Axogen (AXGN) director receives 4,392 RSUs in $185,000 equity grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Axogen, Inc. director Joseph A. Tyndall received a grant of 4,392 restricted stock units as equity compensation for his service on the Board of Directors. Each unit represents a contingent right to receive one share of Axogen common stock.

The annual equity grant is based on a $185,000 valuation as of the grant date and will vest on June 24, 2027, the one-year anniversary of the grant. Following this award, Tyndall holds 4,392 restricted stock units directly, reflecting a routine compensation-related acquisition rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider TYNDALL JOSEPH A.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	4,392	$0.00	--

Holdings After Transaction: Restricted Stock Units — 4,392 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Key Figures

RSUs granted: 4,392 units Grant valuation: $185,000 Units after transaction: 4,392 units +2 more

5 metrics

RSUs granted 4,392 units Restricted stock unit grant to director on June 24, 2026

Grant valuation $185,000 Valuation basis for annual equity grant as of grant date

Units after transaction 4,392 units Total restricted stock units held directly following grant

Underlying common shares 4,392 shares Each RSU represents one share of Axogen common stock

Vesting date June 24, 2027 One-year anniversary of grant date for RSU vesting

Key Terms

Restricted Stock Units, annual equity grant, vests, Board of Directors

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual equity grant financial

"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors."

vests financial

"The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date."

Board of Directors financial

"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 04:53 PM Accepted by SEC EDGAR 06/26/2026 - 04:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TYNDALL JOSEPH A.

(Last)

(First)

(Middle)

C/O AXOGEN, INC. 13631 PROGRESS BLVD.,

SUITE 400

(Street)

ALACHUA

FLORIDA

32615

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	06/24/2026		A		4,392		⁽²⁾	⁽²⁾	Common Stock⁽²⁾	4,392	$0	4,392	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

2. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

Remarks:

	/s/ Marc Began as attorney-in-fact for Joseph A. Tyndall	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Axogen (AXGN) disclose in Joseph Tyndall’s latest Form 4?

Axogen disclosed that director Joseph A. Tyndall received a grant of 4,392 restricted stock units as annual equity compensation. These units are tied to his Board service and convert into common shares if vesting conditions are met on the specified vesting date.

How many restricted stock units did Axogen (AXGN) grant to director Joseph Tyndall?

Axogen granted Joseph A. Tyndall 4,392 restricted stock units. Each unit represents a contingent right to receive one share of Axogen common stock, providing equity-based compensation linked to future service and aligning the director’s interests with long-term shareholder outcomes.

What is the value of Joseph Tyndall’s Axogen (AXGN) equity grant?

The equity grant to Joseph A. Tyndall is based on a valuation of $185,000 as of the grant date. This valuation determines the number of restricted stock units awarded, translating that dollar amount into 4,392 units that may convert into common shares upon vesting.

When do Joseph Tyndall’s Axogen (AXGN) restricted stock units vest?

Joseph A. Tyndall’s 4,392 restricted stock units vest on June 24, 2027. This date is the one-year anniversary of the grant, meaning the units convert into Axogen common stock only if vesting conditions tied to his Board service are satisfied.

Is Joseph Tyndall’s Axogen (AXGN) Form 4 transaction an open-market stock purchase?

No, the transaction is an equity grant, not an open-market purchase. The Form 4 shows a compensation-related award of restricted stock units at zero purchase price, reflecting Board service rather than a discretionary buy of Axogen shares in the public market.